Last reviewed · How we verify
Pulmonary lymphangioleiomyomatosis
Approved treatments
- Rapamune · Wyeth is now a wholly owned subsidiary of Pfizer
- Rapamune · Pfizer
Rapamune works by binding to the mTOR protein, inhibiting its activity and preventing the growth and proliferation of certain cells. - Rapamycin · Institut National de la Santé Et de la Recherche Médicale, France
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Pulmonary lymphangioleiomyomatosis patent landscape — cliff calendar, originator estates, attackable patents
- Pulmonary lymphangioleiomyomatosis treatment landscape brief
- Pulmonary lymphangioleiomyomatosis treatment updates RSS
Frequently asked questions about Pulmonary lymphangioleiomyomatosis
What drugs treat Pulmonary lymphangioleiomyomatosis?
Tracked treatments include Rapamune, Rapamycin.
What is the treatment for Pulmonary lymphangioleiomyomatosis?
Standard treatment for Pulmonary lymphangioleiomyomatosis includes Rapamune, Rapamycin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Pulmonary lymphangioleiomyomatosis patent cliff · Pulmonary lymphangioleiomyomatosis CI report
- Treatment: Rapamune · Wyeth is now a wholly owned subsidiary of Pfizer
- Treatment: Rapamune · Pfizer
- Treatment: Rapamycin · Institut National de la Santé Et de la Recherche Médicale, France
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing